Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline Review, H2 2016’, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF)

The report reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics and enlists all their major and minor projects

The report assesses Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Celgene Corporation

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Italfarmaco S.p.A.

JW Pharmaceutical Corporation

MedImmune, LLC

MEI Pharma, Inc.

Nippon Shinyaku Co., Ltd.

Novartis AG

Pfizer Inc.

Promedior, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview 7

Therapeutics Development 8

Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview 8

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Development by Companies 9

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Development by Companies 13

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development 14

Celgene Corporation 14

F. Hoffmann-La Roche Ltd. 15

Gilead Sciences, Inc. 16

Incyte Corporation 17

Italfarmaco S.p.A. 18

JW Pharmaceutical Corporation 19

MedImmune, LLC 20

MEI Pharma, Inc. 21

Nippon Shinyaku Co., Ltd. 22

Novartis AG 23

Pfizer Inc. 24

Promedior, Inc. 25

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

buparlisib hydrochloride - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CWP-291 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

durvalumab - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

givinostat - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

glasdegib - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

idelalisib - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

itacitinib adipate - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

LCL-161 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

momelotinib dihydrochloride - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

NS-018 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

pomalidomide - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

pracinostat - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

PRM-151 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

vismodegib - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects 97

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products 98

Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones 99

Featured News & Press Releases 99

Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting 99

Appendix 101

Methodology 101

Coverage 101

Secondary Research 101

Primary Research 101

Expert Panel Validation 101

Contact Us 101

Disclaimer 102

List of Tables

List of Tables

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Celgene Corporation, H2 2016 14

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 15

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Gilead Sciences, Inc., H2 2016 16

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Incyte Corporation, H2 2016 17

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Italfarmaco S.p.A., H2 2016 18

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by JW Pharmaceutical Corporation, H2 2016 19

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by MedImmune, LLC, H2 2016 20

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by MEI Pharma, Inc., H2 2016 21

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 22

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Novartis AG, H2 2016 23

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Pfizer Inc., H2 2016 24

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Promedior, Inc., H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 32

Number of Products by Stage and Molecule Type, H2 2016 34

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Dormant Projects, H2 2016 97

Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Discontinued Products, H2 2016 98

List of Figures

List of Figures

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Top 10 Targets, H2 2016 27

Number of Products by Stage and Top 10 Targets, H2 2016 27

Number of Products by Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 29

Number of Products by Routes of Administration, H2 2016 31

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 33

Number of Products by Stage and Molecule Types, H2 2016 33

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports